TITLE

Briefly…

PUB. DATE
July 2008
SOURCE
Cardiovascular Devices & Drugs;Jul2008, Vol. 14 Issue 7, p18
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article covers issues on the pharmaceutical industry as of July 2008. According to a data from Actelion, bosentan hindered clinical deterioration in patients with mildly symptomatic pulmonary arterial hypertension (PAH). About $2.6 million has been raised by BSP in a private funding round that comprised its existing shareholders and new investors. Metabasis Therapeutics claimed that its Phase Ib drug trial in patients with mild hypercholesteromia revealed that MB07811 was safe and well tolerated across the seven doses examined.
ACCESSION #
33516928

 

Related Articles

  • FDA/EMA ROUNDUP.  // MondayMorning;12/17/2012, Vol. 20 Issue 48, p1 

    The article offers news briefs related to pharmaceutical industry as of December 17, 2012. Drugs to treat two rare types of blood cancer from Ariad Pharmaceuticals Inc. have been approved by the U.S. Food & Drug Administration (FDA). FDA has announced to evaluate the macitentan drug from...

  • COMPANY SPOTLIGHT - Actelion Ltd.  // PharmaWatch: Biotechnology;Jun2009, Vol. 8 Issue 6, p24 

    The article presents a corporate profile of Actelion Ltd., a Swiss biopharmaceutical company. The company is involved in discovering, developing and commercializing drugs for the treatment of cardiovascular disorders, central nervous system disorders, genetic disorders, immunological disorders,...

  • Actelion Pays for Option to Buy Trophos for up to $251M. Moran, Nuala // BioWorld International;7/21/2010, Vol. 15 Issue 29, p1 

    The article reports on the decision of Actelion Pharmaceuticals Ltd. to pay 10 million euros in cash for the option to purchase Trophos SA. The acquisition, valued at up to 195 million euros, will be made once results have been released by Trophos from a phase III trial of its olesoxime drug for...

  • Actelion starts miglustat Phase II study for cystic fibrosis.  // PharmaWatch: Biotechnology;Nov2007, Vol. 6 Issue 11, p4 

    The article reports that Actelion Ltd. has started the Phase IIa study of miglustat for the treatment of cystic fibrosis. It expects that the full results of this study will become available at the end of 2008. Chief executive officer Jean-Paul Clozel stresses that the firm's decision to engage...

  • TOP STORIES.  // MondayMorning;11/22/2010, Vol. 18 Issue 43, p1 

    The article offers news briefs related to drug industry in the U.S. Amgen Inc. will acquire Actelion Ltd. A drug from Merck & Co. has helped in minimizing the complications of heart diseases. A gene-therapy treatment called Mydica which has been made by Celladon Corp. has helped patients with...

  • NEW PRODUCT NEWSWIRE.  // Drug Topics;2/9/2004, Vol. 148 Issue 3, p119 

    Features various health products for the pharmaceutical industry in the U.S. Availability of Zavesca capsules from Actelion Pharmaceuticals Inc.; Use of Eloxatin developed by Sanofi-Synthelabo Inc. in the treatment of metastatic colorectal cancer; Specification of Seroquel tablets manufactured...

  • DATAMONITOR: Actelion Ltd.  // Actelion Ltd SWOT Analysis;Apr2010, p1 

    A company profile of Actelion Ltd., a Switzerland-based biopharmaceutical company is presented. An overview of the company is given, along with key facts including contact information and operating profit. . A SWOT analysis is provided which includes strengths, weaknesses, opportunities for...

  • COMPANY SPOTLIGHT - Actelion Ltd.  // PharmaWatch: Monthly Review;Jun2009, Vol. 8 Issue 6, p50 

    The article profiles Actelion Ltd., a biopharmaceutical company in Switzerland. The company engages in discovering, developing and commercializing drugs for cardiovascular disorders, central nervous system disorders and genetic disorders. It presents strengths, weaknesses, opportunities, and...

  • Actelion Gains Rights to Auxilium's Xiaflex in Canada, Australia, Brazil and Mexico. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 3, p35 

    Actelion Pharmaceuticals has gained the rights to develop and commercialise Auxilium Pharmaceuticals' Xiaflex® (collagenase clostridium histolyticum), a first-in-class biologic for Dupuytren's contracture (DC) and Peyronie's disease (PD), in Canada, Australia, Brazil and Mexico in a deal...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics